22 January 2021 (Friday) - A.S.H. Update


The nice people at the American Society of Hematology sent an update on chronic leukaemias today:

Asciminib Beats Bosutinib in Treatment-Resistant Chronic Myeloid Leukemia
Asciminib was more effective at achieving major molecular response than bosutinib in patients with resistant/intolerant CML, according to late-breaking results of the ASCEMBL study presented at the 2020 ASH Annual Meeting.
FDA Approves Ponatinib for Chronic-Phase CML
The agency has approved the supplemental new drug application for ponatinib to treat adults with chronic-phase CML that is resistant or intolerant to at least two prior kinase inhibitors.
Study Identifies Key Mutations That Promote Stem Cell Growth and Increase Leukemia Risk
Researchers linked three genetic loci to the increased proliferation of hematopoietic stem cells, which may subsequently increase the risk of CHIP and malignancies


No comments:

Post a Comment